title: Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy.
abstract: To investigate the changes in the intrachoroidal structures after half-dose verteporfin photodynamic therapy (PDT) for central serous chorioretinopathy (CSC).
  
  
  
  Swept-source optical coherence tomography cross-sectional images of 22 eyes of 22 patients with CSC were retrospectively analysed by a manual delineation technique and binarisation method.
  
  
  
  In the 22 eyes, the mean subfoveal choroidal thickness decreased from 412.9±112.9 μm at baseline to 340.0±111.0 μm at 3 months (p<0.0001). The mean thickness of the large choroidal vessel layer decreased from 368.7±112.7 μm at baseline to 292.2±118.0 μm at 3 months (p<0.0001), but the mean choriocapillaris-medium choroidal vessel layer thickness did not change from 44.2±29.2 μm at baseline to 47.8±25.7 μm at 3 months (p=0.85). Analyses of the binarised choroidal images showed that a 3 mm subfoveal choroidal area decreased from 1.141±0.290 mm2at baseline to 0.962±0.320 mm2at 3 months after PDT (p=0.0001). The mean luminal areas decreased from 0.826±0.246 mm2at baseline to 0.665±0.234 mm2at 3 months (p=0.0001), however, the mean stromal areas did not change from 0.315±0.066 mm2at baseline to 0.297±0.095 mm2at 3 months (p=0.60).
  
  
  
  Half-dose PDT reduces subfoveal choroidal thickness and alters the intrachoroidal structures in eyes with CSC.
authors.affiliation: Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Takahiko
authors.initials: T
authors.lastname: Izumi
authors.affiliation: Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Koizumi
authors.affiliation: Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Maruko
authors.affiliation: Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Takahashi
authors.affiliation: Department of Ophthalmology, Kagoshima University, Kagoshima, Japan.
authors.forename: Shozo
authors.initials: S
authors.lastname: Sonoda
authors.affiliation: Department of Ophthalmology, Kagoshima University, Kagoshima, Japan.
authors.forename: Taiji
authors.initials: T
authors.lastname: Sakamoto
authors.affiliation: Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Iida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D056833:Central Serous Chorioretinopathy / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D002829:Choroid / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin
keywords: Choroid; Imaging; Macula; Treatment Lasers; Treatment Medical